Telix Pharmaceuticals Limited
TLX
$17.72
$0.42362.45%
Weiss Ratings | TLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Fair | |||
Risk Index | Weak | |||
Risk Grade | D+ | |||
Reward Grade | C | |||
Rating Factors | TLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Good | |||
Efficiency Index | Fair | |||
Solvency Index | Excellent | |||
Total Return Index | Weak | |||
Volatility Index | Good | |||
Beta / Standard Deviation | TLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | -- | |||
Price History | TLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -0.71% | |||
30-Day Total Return | -6.22% | |||
60-Day Total Return | 10.70% | |||
90-Day Total Return | -- | |||
Year to Date Total Return | 18.16% | |||
1-Year Total Return | -- | |||
2-Year Total Return | -- | |||
3-Year Total Return | -- | |||
5-Year Total Return | -- | |||
52-Week High % Change | -43.02% | |||
52-Week Low % Change | 23.48% | |||
Price | TLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $30.36 | |||
52-Week Low Price | $14.01 | |||
52-Week Low Price (Date) | Jan 13, 2025 | |||
52-Week High Price (Date) | Feb 24, 2025 | |||
Valuation | TLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 5.71B | |||
Enterprise Value | 5.63B | |||
Price/Earnings (TTM) | 180.40 | |||
Earnings Per Share (TTM) | 0.10 | |||
Earnings Per Share Growth | 1,069.51% | |||
Price/Earnings To Growth | 0.17 | |||
Price/Sales (TTM) | 11.77 | |||
Price/Book (Q) | 16.47 | |||
Enterprise Value/Revenue (TTM) | 10.89 | |||
Price | $17.72 | |||
Enterprise Value/EBITDA (TTM) | 97.41 | |||
Enterprise Value/EBIT | 104.18 | |||
Market Cap Category | Mid Cap | |||
Dividends and Shares | TLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 351.47M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | TLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 61 3 9093 3855 | |||
Address | 55 Flemington Road North Melbourne, VIC 3051 | |||
Website | telixpharma.com | |||
Country | Australia | |||
Year Founded | 2015 | |||
Profitability | TLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | 10.45% | |||
Profit Margin | 6.36% | |||
Management Effectiveness | TLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | 5.55% | |||
Return on Equity | 14.52% | |||
Income Statement | TLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 516.66M | |||
Total Revenue (TTM) | 516.66M | |||
Revenue Per Share | $1.47 | |||
Gross Profit (TTM) | 319.24M | |||
EBITDA (TTM) | 57.74M | |||
EBIT (TTM) | 54.00M | |||
Net Income (TTM) | 32.91M | |||
Net Income Avl. to Common (TTM) | 32.91M | |||
Total Revenue Growth (Q YOY) | 48.80% | |||
Earnings Growth (Q YOY) | 3.75% | |||
EPS Diluted (TTM) | 0.10 | |||
EPS Diluted Growth (Q YOY) | -2.59% | |||
Balance Sheet | TLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 439.60M | |||
Cash Per Share (Q) | $1.25 | |||
Total Current Assets (Q) | 568.45M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 351.64M | |||
Current Ratio (Q) | 2.776 | |||
Book Value Per Share (Q) | $1.05 | |||
Total Assets (Q) | 938.44M | |||
Total Current Liabilities (Q) | 204.79M | |||
Total Debt (Q) | 359.83M | |||
Total Liabilities (Q) | 586.80M | |||
Total Common Equity (Q) | 351.64M | |||
Cash Flow | TLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -89.23M | |||
Cash from Financing (TTM) | 422.22M | |||
Net Change in Cash (TTM) | 387.99M | |||
Levered Free Cash Flow (TTM) | 46.47M | |||
Cash from Operations (TTM) | 28.36M | |||